Concerning the five mutations of which the characterization is unprecedented, in the future the availability of patient-derived NSCLC cell lines harboring these BRAF mutations would help broaden our knowledge regarding mechanism of oncogenesis and drug response. This evidence concerns the gene BRAF and non-small cell lung carcinoma.